X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA DIVIS LABORATORIES SHASUN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 123.9 33.6 368.6% View Chart
P/BV x 8.5 5.5 156.4% View Chart
Dividend Yield % 0.2 0.9 25.7%  

Financials

 SHASUN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
DIVIS LABORATORIES
Mar-17
SHASUN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs941,222 7.7%   
Low Rs46784 5.8%   
Sales per share (Unadj.) Rs214.2153.1 139.9%  
Earnings per share (Unadj.) Rs5.339.9 13.4%  
Cash flow per share (Unadj.) Rs15.844.6 35.5%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %1.41.0 143.5%  
Book value per share (Unadj.) Rs53.3201.8 26.4%  
Shares outstanding (eoy) m56.62265.47 21.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.6 5.0%   
Avg P/E ratio x13.125.1 52.2%  
P/CF ratio (eoy) x4.422.5 19.6%  
Price / Book Value ratio x1.35.0 26.4%  
Dividend payout %18.725.0 74.9%   
Avg Mkt Cap Rs m3,958266,266 1.5%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m2,1644,687 46.2%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m12,12740,643 29.8%  
Other income Rs m229749 30.6%   
Total revenues Rs m12,35641,392 29.9%   
Gross profit Rs m1,00914,460 7.0%  
Depreciation Rs m5941,233 48.1%   
Interest Rs m41523 1,836.7%   
Profit before tax Rs m23013,953 1.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-733,349 -2.2%   
Profit after tax Rs m30210,604 2.8%  
Gross profit margin %8.335.6 23.4%  
Effective tax rate %-31.724.0 -131.9%   
Net profit margin %2.526.1 9.5%  
BALANCE SHEET DATA
Current assets Rs m6,88440,105 17.2%   
Current liabilities Rs m8,4566,595 128.2%   
Net working cap to sales %-13.082.5 -15.7%  
Current ratio x0.86.1 13.4%  
Inventory Days Days62119 52.0%  
Debtors Days Days10881 133.3%  
Net fixed assets Rs m4,97019,995 24.9%   
Share capital Rs m113531 21.3%   
"Free" reserves Rs m2,87553,043 5.4%   
Net worth Rs m3,02053,574 5.6%   
Long term debt Rs m1,8170-   
Total assets Rs m13,34761,585 21.7%  
Interest coverage x1.6618.4 0.3%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.90.7 137.7%   
Return on assets %5.417.3 31.1%  
Return on equity %10.019.8 50.5%  
Return on capital %13.326.1 51.1%  
Exports to sales %46.40-   
Imports to sales %14.225.2 56.4%   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,72810,259 16.8%   
Fx inflow Rs m5,84335,384 16.5%   
Fx outflow Rs m2,17310,399 20.9%   
Net fx Rs m3,66924,985 14.7%   
CASH FLOW
From Operations Rs m39811,493 3.5%  
From Investments Rs m-1,635-11,372 14.4%  
From Financial Activity Rs m1,309-93 -1,405.6%  
Net Cashflow Rs m7128 250.7%  

Share Holding

Indian Promoters % 39.2 52.0 75.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 11.8 30.5%  
FIIs % 17.6 19.0 92.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.2 230.2%  
Shareholders   20,750 31,796 65.3%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  MERCK LTD  NOVARTIS  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS